Pegloticase
Pegloticase Uses, Dosage, Side Effects, Food Interaction and all others data.
Pegloticase is a recombinant porcine-like uricase drug indicated for the treatment of severe, treatment-refractory, chronic gout. Similarly to rasburicase, pegloticase metabolises the conversion of uric acid to allantoin. This reduces the risk of precipitate formation and development of gout, since allantoin is five to ten times more soluble than uric acid. Pegloticase is a pegylated form of uricase which offers an extended half-life of ten-12 days compared to rasburicase's 8 hours. It also offers reduced immunogenicity due to the bulky PEG group. The longer haf-life allows for less frequent dosing at once every 2-4 weeks making pegloticase more convenient for chronic use.
Trade Name | Pegloticase |
Availability | Prescription only |
Generic | Pegloticase |
Pegloticase Other Names | Pegloticase, Puricase |
Related Drugs | allopurinol, febuxostat, Zyloprim, probenecid, Uloric, Krystexxa |
Weight | 8mg/ml, |
Type | Intravenous Solution, Intravenous |
Formula | C1549H2430N408O448S8 |
Weight | 34192.8533 Da |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Pegloticase is a recombinant uricase used for the treatment of chronic gout in adult patients refractory to conventional therapy.
For the treatment of chronic gout in adult patients refractory to conventional therapy.
Pegloticase is also used to associated treatment for these conditions: Chronic, refractory Gout
How Pegloticase works
Pegloticase is a recombinant uricase that catalyzes the metabolism of uric acid to allantoin.
Toxicity
Conditions that should be monitored for when starting treatment with pegloticase include anaphylaxis, infusion reactions, an increase in gout flares, and/or an exacerbation of pre-existing congestive heart failure.
Food Interaction
No interactions found.Pegloticase Disease Interaction
Elimination Route
Approximately 24 hours following the first dose, mean plasma uric acid levels were 0.7 mg/dL. The duration of suppression of plasma uric acid appeared to be positively associated with pegloticase dose. Sustained decrease in plasma uric acid below the solubility concentration of 6 mg/dL for more than 300 hours was observed with doses of 8 mg and 12 mg.
Innovators Monograph
You find simplified version here Pegloticase